smallsize_on_transparent_by_logaster

A Swiss-Singaporean Private Equity Firm

Those who survive are not the strongest or the most intelligent, but the most adaptable to change.

Darwin

Our Identity

An international private equity and venture capital firm, with an euro-asian double-culture and an extensive experience assisting Tech companies during all critical phases.

Since 2005, we provide straight-forward, unconflicted advice and access to private capital to startups and mid-market companies in the most innovative sectors, in Europe, Asia and Middle East.

80

US$m raised

in our three active investment funds.

1

Companies we are invested in

in Europe, Middle East and South-East Asia.

100

Companies screened in 2019

from startups to mid-market companies.

Our Values

Determination

Accountability

Adaptability

Our Approach

It is about passion and dedication.
Dedicated to growth acceleration
& Into long-term relationships.
We love innovation and new ideas !

… From vision to value !

Our Geography

Catching the best opportunities where they are !

From Zurich

40% invested in Europe and Middle East, from Zurich, the 1st mainland Europe Financial Center, with a fledgling FinTech scene and a dynamic innovation driver for life sciences in Europe.

From Singapore

60% invested in Southeast Asia, from Singapore, the “pro-business city”, one of Asia’s largest trading hubs, with four billion opportunities within a seven-hour flight radius.

Our Funds

ARIETIS started in 2005, investing in Swiss Biotech and Fintech startups. Now ARIETIS is investing more widely in the best Tech companies. ARIETIS INVEST AG is FINMA regulated since 2006 and MAS regulated since 2009.

Our 3 active investment funds, with US$340m raised, are supporting the best innovations in Europe, South-East Asia and Middle East.

ARIETIS GROWTH GP AG

European & Middle East IT, biotech and Tech Cies.
Since 2019.

US$110m raised

ARIETIS INNOSIGHT ASIA 2 LTD

South-East Asia innovative startups.
Since 2017.

US$150m raised

ARIETIS BIOTECH EURO GP AG

focused on Biotech startups at early stage.
Since 2013.

US$80m raised

Our Portofolio

We invest in the best tech startups and grant them access to our large high-quality network, over Europe, Asia and Middle East.

39 great ideas now being changed into value !

Get to know & contact us :